Every year, we work closely with founders and leadership teams toward achieving a shared goal: build market-leading businesses that positively impact healthcare.
This commitment and clarity of purpose have resulted in another active, outstanding year for Water Street and our family of healthcare companies.
We have applied our proactive approach to building healthcare leaders since our founding in 2005, delivering consistent results and contributing to a stronger healthcare system through many economic and market cycles.
Bolstering Water Street’s Greatest Asset: Our People
Joseph C. Papa and Ari Kellen joined Water Street to support our search for our next specialty pharmaceutical investment.
Avi Pelossof is working with us on opportunities to invest in diagnostics and life sciences businesses.
Boris Bernstein, a longtime Water Street Executive Advisor, was appointed to Managing Director in Europe.
John Orlando joined our team to support our companies with technology strategies that advance their business objectives.
New associates Paty Calderon, Dan Pascetta and Grace Rodgers support our growing group of companies.
A new partnership focused on building on Avantik’s legacy as a trusted resource serving diagnostic laboratories.
Partnered with founders to build a provider offering comprehensive solutions to support employers with intensifying healthcare compliance demands.
Expanded the biospecimen and biomarker provider’s cell biology and toxicology services with the addition of ReachBio Research Labs.
Acquired Healthware Group to amplify the company’s global footprint and commercial capabilities supporting life science organizations.
Facilitated another acquisition to broaden Renovo’s services supporting customers with managing their clinical equipment and technology.
Added another capability to advance the company’s innovative solutions that reduce employer healthcare costs and improve the customer experience.
Completed two acquisitions to bolster the company’s service coverage to diagnostic laboratories on a national scale.
Added four injectable products to grow the company’s portfolio of specialized, complex generic drug formulations.
Opened a global headquarters with state-of-the-art capabilities to support customers seeking to accelerate their R&D initiatives.
Broke ground on a new global headquarters and distribution center to more efficiently provide first responders with critical medical devices and technologies.
Unveiled the company’s lightest medical alert device with instant two-way communications, fall detection technology and other features supporting aging adults.
Invested in advancing diagnostic solutions to support higher-volume labs with assessing patients’ inflammation levels and research market with measuring red blood properties for sepsis testing.
Unveiled clinical data demonstrating the powerful impact of the company’s advanced test for diagnosing complicated, recurrent UTIs.
Selected to serve as the new R&D partner to the U.S. Administration for Strategic Preparedness and Response among other new clients.
Invested significant capital to more than double Viant’s presence and workforce in Costa Rica.
Founded in 1971, Avantik has steadily worked to become a trusted service provider to diagnostic laboratories. When the founding family decided it was time …
Today’s intensifying health insurance regulatory environment is profoundly impacting U.S. employers. We formed Compliance Services, …
Since merging three businesses to create Discovery Life Sciences five years ago, we have collaborated with Discovery’s management team …
At Water Street, creating meaningful long-term value has always been about collaboration with strong executives and a continuous search together for new ways to build businesses, turn healthcare challenges into opportunities and contribute to a more efficient, effective healthcare system.
We advance through new ideas, new relationships and new opportunities.
Work with us.
This presentation is for information purposes only and is not intended as investment advice or an offer or solicitation with respect to the purchase or sale of any security. Offers to sell or solicitations to invest in a Water Street Fund (“Fund”) are made only by means of a confidential offering memorandum, limited partnership agreement (or other organizational document) and any subscription agreement and in accordance with applicable securities laws.
Past performance is not indicative, nor a guarantee, of future results, which may vary. An investment in a Water Street Fund is a speculative investment and involves significant risks, including the potential loss of all or a substantial portion of invested capital, the use of leverage and the lack of liquidity of an investment. Any investment in a Fund is subject to various risks, none of which are outlined herein. It should not be assumed that future investments will be comparable in quality or performance to the investments described herein.
Aggregate Earnings represents pro-forma EBITDA that has generally been normalized for items considered one-time or non-recurring in nature. The calendar year comparisons versus 2022 includes all active companies, except Long Grove and Lakeview, which are development companies with no earnings or revenue.
The investments listed in this Year in Review do not represent all the investments made by Water Street. Please see our website for a list of all investments.
The title “Operating Partner” is not intended to indicate that a team member with this title is a partner, principal or employee of Water Street or any Water Street Fund or other affiliate. Operating Partners provide expertise to Water Street and its portfolio companies and are typically compensated by such portfolio companies. They may be independent contractors or employees of current or former portfolio companies and may have business or investment activities unrelated to Water Street.
Corporate Resource Group members are employees of Water Street who provide services to a Water Street Fund or a portfolio company and are compensated by such Fund or portfolio company.
Testimonials of CEOs are provided to demonstrate the benefits of working with the Water Street team and are not provided to solicit an investor in a Water Street fund. No CEO was paid for their testimonial. There is a conflict of interest in that the CEOs stand to benefit from Water Street's success and their company is owned by a Water Street fund.